{
    "id": 15097,
    "fullName": "EPHA2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EPHA2 over exp indicates an over expression of the Epha2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1969,
        "geneSymbol": "EPHA2",
        "terms": [
            "EPHA2",
            "ARCC2",
            "CTPA",
            "CTPP1",
            "CTRCT6",
            "ECK"
        ]
    },
    "variant": "over exp",
    "createDate": "12/10/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17263,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells with EPHA2 overexpression were resistant to treatment with Erbitux (cetuximab) in culture and in xenograft models, demonstrating increased tumor volume (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17269,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase II trial, the combination treatment of Erbitux (cetuximab) plus Adrucil (fluorouracil), Camptosar (irinotecan), and Wellcovorin (leucovorin) resulted in a shorter progression-free survival (8.6 vs 12.3 mo; p=0.03) and a trend towards a greater decreased overall survival (28.4 vs 39.8 mo) in colorectal cancer patients with overexpression of EPHA2 compared to those patients with low EPHA2 expression (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17265,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of ALW-II-41-27 and Erbitux (cetuximab) resulted in a synergistic effect in colorectal cancer cells overexpressing EPHA2 in culture, demonstrating antiproliferation activity, increased apoptosis, and cell cycle arrest, and led to a partial response in nine out of ten xenograft models, with a tumor reduction greater than 35% (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 8441,
                "therapyName": "ALW-II-41-27 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17264,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells overexpressing EPHA2 were sensitive to treatment with ALW-II-41-27, demonstrating reduced cell proliferation in culture and stable disease in xenograft models (PMID: 30824612).",
            "molecularProfile": {
                "id": 15353,
                "profileName": "EPHA2 over exp"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15299,
                    "pubMedId": 30824612,
                    "title": "EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30824612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4266,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALW-II-41-27 reduced survival of a Tarceva (erlotinib)-resistant non-small cell lung cancer cell line harboring both EGFR E746_A750del and T790M and overexpressing EphA2 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26744526).",
            "molecularProfile": {
                "id": 17585,
                "profileName": "EGFR E746_A750del EGFR T790M EPHA2 over exp"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4472,
                    "pubMedId": 26744526,
                    "title": "EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744526"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15353,
            "profileName": "EPHA2 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 7212,
                    "name": "ALW-II-41-27",
                    "profileName": "EPHA2 over exp"
                }
            ]
        },
        {
            "id": 17585,
            "profileName": "EGFR E746_A750del EGFR T790M EPHA2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}